Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Heart (British Cardiac Society)|April 19, 2017
Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular riskRobert D Brook, Julie A Anderson, Peter Ma Calverley, et al.
Annals of the American Thoracic Society|December 10, 2014
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPDCourtney Crim, Mark T Dransfield, Jean Bourbeau, et al.
BMJ Open Respiratory Research|July 2, 2019
Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trialBartolome R Celli, Julie A Anderson, Robert Brook, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsMark T Dransfield, Jean Bourbeau, Paul W Jones, et al.
American Journal of Respiratory and Critical Care Medicine|October 22, 2016
Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow ObstructionFernando J Martinez, Jørgen Vestbo, Julie A Anderson, et al.
Annals of the American Thoracic Society|February 7, 2018
β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMITMark T Dransfield, David A McAllister, Julie A Anderson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 18, 2020
FEV<sub>1</sub> is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular diseaseAndras Bikov, Peter Lange, Julie A Anderson, et al.
Journal of the American College of Cardiology|September 1, 2018
Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary DiseasePhilip D Adamson, Julie A Anderson, Robert D Brook, et al.
The European Respiratory Journal|June 15, 2013
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohortAlvar Agusti, Lisa D Edwards, Bartolomé Celli, et al.
Thorax|June 15, 2012
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary diseasePaul Albert, Alvar Agusti, Lisa Edwards, et al.
Pageof 9